long peptides & fat loss drugs https://t.co/VTakJR0c1O ...

Core Insights - Apollo Biowellness, Inc. is updating shareholders on corporate developments and the merger with Revive Regenerative, Inc. [1] - The merger's original closing date was October 30, 2025, but an extension of approximately 30 days is needed to complete the process [1] - The company is negotiating to convert all debt to equity as a condition for closing the merger [1] Corporate Developments - The company has completed initial bridge financing of $500,000 for the merger and is seeking an additional $3,000,000 as per the Merger Agreement [1] - A definitive update on the debt conversion is expected within the next 7 to 10 days [1] - The company is also negotiating with a tele-med GPL-1 Peptide company to expand its product offerings [1] Product and Market Positioning - The merger aims to create a fully integrated company combining laser and energy devices with exosome-based biologic aesthetic products and GLP-1 weight loss products [3] - This integration is expected to significantly increase top-line revenues and enhance EBITDA [3] - Apollo Biowellness is positioning itself as a leader in Regenerative Medicine, focusing on biologic-based products [4]

Summary of Conference Call on China's CDMO Industry and WuXi Companies Industry Overview - The Chinese Contract Development and Manufacturing Organization (CDMO) segment has seen increased investor interest since early 2025, driven by favorable fundamentals despite geopolitical tensions [1] - Concerns about overcapacity in the CDMO industry are being evaluated, with current capacity utilization reported at approximately 80%, indicating a healthy demand-supply balance [2] Key Insights on WuXi Companies WuXi Biologics - The company faces significant geopolitical risks, particularly from U.S. trade initiatives aimed at reshoring drug manufacturing and price cuts on prescription drugs [2] - Approximately 60% of WuXi Biologics' revenue is derived from U.S. customers, leading to stock trading within a forward P/E range of 20x to 45x based on these geopolitical developments [2] WuXi XDC - WuXi XDC is projected to have capital expenditures exceeding RMB 1.4 billion in 2025, with a cash balance of RMB 3.5 billion at the end of 2024 and a net profit of RMB 1.1 billion in 2024 [3] - The company indicated a preference for raising funds through debt rather than equity if necessary [3] WuXi AppTec - WuXi AppTec is significantly involved in the rapidly growing GLP-1 market, with contracts for peptides and oligonucleotides contributing 23% of its revenue in Q1 2025 [4] - The company expects its backlog and capacity to double in 2025, with segment revenue anticipated to increase by over 60% [4] - WuXi AppTec holds a market share of approximately 20% in CDMO contracts and has over 20 ongoing projects in the GLP-1 market [4] Additional Considerations - The complexity of drug modalities is leading to increased outsourcing from biopharma companies, with outsourcing rates ranging from 30% to 80% of R&D spending [2] - The demand for bioconjugates and peptides is outpacing supply, which is beneficial for WuXi XDC and WuXi AppTec [2] - The overall industry view remains attractive, with potential for growth driven by increasing orders and successful product launches [7] Risks and Opportunities - Risks include geopolitical tensions, potential funding deceleration in biotech, and competition in the global market [15][17] - Opportunities may arise from favorable government policies, margin expansion, and increased outsourcing of R&D globally [15][16] This summary encapsulates the key points discussed in the conference call regarding the Chinese CDMO industry and the performance and outlook of WuXi companies.